TargetBeta
GNRHR
gonadotropin releasing hormone receptor · also LHRHR, GRHR · Gonadotropin releasing hormone receptors
7 programs in company-led studies act on GNRHR, from 7 companies: 4 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Leuproliderule | Takeda | phase 4 | 392 running | – | ChEMBL |
| Goserelinrule | AstraZeneca | phase 4 | 141 running | GNRH1 | ChEMBL |
| triptorelinrule | Ipsen | phase 4 | 210 running | GNRH1 | ChEMBL |
| linzagolixrule | Kissei Pharmaceutical | phase 3 | 141 running | – | ChEMBL |
| GnRH Antagonist SHR7280 | Jiangsu HengRui Medicine | phase 3 | 101 running | – | the company's pipeline |
| Gonadotropin-Releasing Hormonerule | Ferring Pharmaceuticals | phase 3 | 51 running | – | ChEMBL |
| leuprolide mesylaterule | Foresee Pharmaceuticals | phase 3 | 30 running | – | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Prostatic Neoplasms, 5 programs
- Endometriosis, 3 programs
- Breast Neoplasms, 2 programs
- Leiomyoma, 2 programs
- Puberty, Precocious, 2 programs
- Alzheimer Disease, 1 program
- Amenorrhea, 1 program
- Hepatic Insufficiency, 1 program
- Infertility, 1 program
- Metrorrhagia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 30, 2027Goserelin · AstraZeneca · phase 4 · NCT07310420
- Nov 2027linzagolix · Kissei Pharmaceutical · phase 3 · NCT07015268
- Feb 28, 2028Gonadotropin-Releasing Hormone · Ferring Pharmaceuticals · phase 3 · NCT04931342
- Aug 30, 2029Leuprolide · Takeda · phase 4 · NCT07710430
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.